HK Stock Market Move | CSTONE PHARMA-B(02616) rises more than 4%, CS2015 will debut at ACAAi 2025.

CSTONE PHARMA-B(02616) rose more than 4%, as of the time of publication, it had risen 4.3% to 10.43 Hong Kong dollars, with a turnover of 109 million Hong Kong dollars. In terms of news, Cornerstone Pharmaceuticals announced this morning that one of its own immune and inflammation pipeline, CS2015 (OX40L/TSLP bispecific antibody), has been selected for the 2025 American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting and will be presented in the form of "electronic poster presentation + on-site oral presentation." The conference will be held in Orlando, USA from November 6th to 10th. It is reported that CS2015 is a potential first-in-class/best-in-class bispecific antibody targeting OX40L and TSLP, which double-inhibits key regulatory factors of Th2-mediated inflammatory reactions, providing new treatment strategies for type 2 inflammatory diseases such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD). Guotou Securities previously pointed out that among the company's early pipeline, ADC product pipeline CS5007 (EGFR/HER3 bispecific ADC), CS5008 (DLL3/SSTR2 bispecific ADC), CS5005 (SSTR2 ADC), CS5006 (ITGB4ADC), and CS5009 (B7H3/PD-L1 bispecific ADC), as well as the self-immune pipeline CS2013 (BAFF/APRIL bispecific antibody), CS2015 (OX40L/TSLP bispecific antibody), are all differentiated varieties with high potential, and the subsequent clinical progress is worth attention.